| Autor: |
Beekman KE; USF Health, Morsani College of Medicine, Tampa, Florida., Parker LM; USF Health, Morsani College of Medicine, Tampa, Florida., DePalo DK; Department of Cutaneous Oncology, Moffitt Cancer Center, Wesley Chapel, Florida., Elleson KM; Department of Cutaneous Oncology, Moffitt Cancer Center, Wesley Chapel, Florida., Sarnaik AA; USF Health, Morsani College of Medicine, Tampa, Florida.; Department of Cutaneous Oncology, Moffitt Cancer Center, Wesley Chapel, Florida., Tsai KY; Department of Anatomic Pathology and Tumor Biology, Moffitt Cancer Center, Wesley Chapel, Florida., Withycombe BM; Department of Pharmacy, Moffitt Cancer Center, Wesley Chapel, Florida., Zager JS; USF Health, Morsani College of Medicine, Tampa, Florida.; Department of Cutaneous Oncology, Moffitt Cancer Center, Wesley Chapel, Florida. |
| Abstrakt: |
Competing Interests: Dr Zager has advisory board relationships and has received fees from with Merck, Novartis, Philogen, Castle Biosciences, Pfizer, and Sun Pharma. He also received research funding from Amgen, Delcath Systems, Philogen, Provectus, and Novartis. He serves on the medical advisory board for Delcath Systems. Dr Sarnaik is a coinventor on a patent application with Provectus Biopharmaceuticals. He has received ad hoc consulting fees from Iovance Biotherapeutics, Guidepoint, Defined Health, Huron Consulting Group, KeyQuest Health Inc, Istari, Rising Tide, and Gerson Lehrman Group. He has received speaker fees from the Society for Immunotherapy of Cancer, Physicians’ Educational Resource LLC, Medscape, and Medstar Health. The remaining authors have no relevant conflicts of interest to disclose. |
